| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Research Abstract |
We examined whether nm23-H1 is a prognostic factor of DLBCL in the rituximab-era. The subjects were DLBCL patients who underwent chemotherapy and in whom markers could be analyzed. Among DLBCL patients who underwent chemotherapy, BCL2-positivity, MUM1-positivity, non-GCB, and nm23-H1-positivity were associated with significantly shorter overall survival and progression-free survival. We demonstrated that among patients with DLBCL who underwent chemotherapy, patients with nm23-H1 expression had a significantly poorer prognosis than patients without nm23-H1 expression. These results suggest an important role for nm23-H1 in malignant progression and a potential therapeutic target for DLBCL.
|
